secwatch / observer
8-K filed February 5, 2025, 6:59 PM ET CIK 0000704562
M&A confidence high sentiment positive materiality 1.00

Avid Bioservices, Inc.: M&A transaction — GHO Capital and Ampersand complete $1.12B acquisition of Avid Bioservices

Avid Bioservices, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Hart

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Daniel Hart was appointed a director of the Company.
Departed

Esther Alegria

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed

Richard Hancock

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed

Joseph Carleone

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed

Gregory Sargen

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed

Jeanne Thoma

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Departed

Catherine Mackey

Director
Avid Bioservices, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel Hart was appointed as Director at Avid Bioservices, Inc..

Action
appointed
Role
Director
Exact text from the filing
Daniel Hart was appointed a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Esther Alegria departed as Director at Avid Bioservices, Inc..

Action
ceased to be a director
Role
Director
Exact text from the filing
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Richard Hancock departed as Director at Avid Bioservices, Inc..

Action
ceased to be a director
Role
Director
Exact text from the filing
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph Carleone departed as Director at Avid Bioservices, Inc..

Action
ceased to be a director
Role
Director
Exact text from the filing
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Gregory Sargen departed as Director at Avid Bioservices, Inc..

Action
ceased to be a director
Role
Director
Exact text from the filing
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Jeanne Thoma departed as Director at Avid Bioservices, Inc..

Action
ceased to be a director
Role
Director
Exact text from the filing
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Catherine Mackey departed as Director at Avid Bioservices, Inc..

Action
ceased to be a director
Role
Director
Exact text from the filing
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Avid Bioservices, Inc.: Certificate of incorporation amended and restated upon Merger completion.

Change
charter amendment
Exact text from the filing
Effective upon completion of the Merger, the certificate of incorporation of the Company, as in effect immediately prior to the Merger, was amended and restated to be in the form of the certificate of incorporation attached as Exhibit 3.1 hereto.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Avid Bioservices, Inc.: Bylaws amended and restated upon Merger completion.

Change
bylaw amendment
Exact text from the filing
Effective upon completion of the Merger, the bylaws of the Company, as in effect immediately prior to the Merger, were amended and restated to be in the form of the bylaws attached as Exhibit 3.2 hereto.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Avid Bioservices, Inc. underwent a change of control involving Space Finco, Inc., Space Mergerco, Inc., GHO Capital Partners LLP and Ampersand Capital Partners for $12.50 in cash (closed 2025-02-05).

Action
change of control
Counterparty
Space Finco, Inc., Space Mergerco, Inc., GHO Capital Partners LLP and Ampersand Capital Partners
Consideration
$12.50 in cash
Closing
2025-02-05
Exact text from the filing
(subject to any adjustment pursuant to the Indenture, including any increase as a result of a Make-Whole Fundamental Change (as defined in the Indenture)) multiplied by $12.50 (which is an amount equal to the Merger Consideration (as defined below)), and a unit of Reference Property under the Indenture will be comprised of an amount in cash equal to
View on SEC.gov

59 governance changes filed in the last 30 days. Browse all governance changes →

Source: SEC EDGAR
accession 0001140361-25-003108
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.